Activity of RX-04 Pyrrolocytosine Protein Synthesis Inhibitors against Multidrug-Resistant Gram-Negative Bacteria-Reference-Cited by-同舟云学术

Activity of RX-04 Pyrrolocytosine Protein Synthesis Inhibitors against Multidrug-Resistant Gram-Negative Bacteria

Published:2018-08 Issue:8 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Vickers Anna¹,Mushtaq Shazad¹,Woodford Neil¹,Doumith Michel¹,Livermore David M.¹²

Affiliation:

1. Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, National Infection Service, Public Health England, London, United Kingdom

2. Norwich Medical School, University of East Anglia, Norwich, Norfolk, United Kingdom

Abstract

Pyrrolocytosines RX-04A to -D are designed to bind to the bacterial 50S ribosomal subunit differently from currently used antibiotics. The four analogs had broad anti-Gram-negative activity: RX-04A—the most active analog—inhibited 94.7% of clinical Enterobacteriaceae , Acinetobacter baumannii , and Pseudomonas aeruginosa at 0.5 to 4 μg/ml, with no MICs of >8 μg/ml.

Funder

Melinta Pharmaceuticals, Inc.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00689-18

Reference17 articles.

1. Use of Antibiotics in Agriculture

2. Blasticidin S inhibits translation by trapping deformed tRNA on the ribosome

3. SAR studies on dihydropyrimidinone antibiotics

4. NMR and Molecular Modelling Studies of the Binding of Amicetin Antibiotic to Conserved Secondary Structural Motifs of 23S Ribosomal RNAs

5. Duffy E, Devivo M, Kanyo Z, Bhattacharjee. 2011. The molecular tuning of RX-04, a novel broad spectrum antibacterial class for coverage of MDR Gram-negative pathogens, abstr FI-1843. Abstr 51st Intersci Conf Antimicrob Agents Chemother.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of Antibacterial Candidates with New Modes of Action;ACS Infectious Diseases;2024-07-17

2. Current and novel therapies for management of Acinetobacter baumannii -associated pneumonia;Critical Reviews in Microbiology;2024-07

3. Virulence Characteristics and Emerging Therapies for Biofilm-Forming Acinetobacter baumannii: A Review;Biology;2022-09-12

4. New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae;Translational Research;2020-06

5. Engineering nucleoside antibiotics toward the development of novel antimicrobial agents;The Journal of Antibiotics;2019-09-09